New COVID-19 drug candidate passes first safety check in healthy volunteers
NCT ID NCT07518771
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety and tolerability of a new drug called PA-001 in 47 healthy and elderly volunteers. Participants received either PA-001 or a placebo through an IV. The main goal was to see if the drug causes any side effects and to understand how the body processes it. This information will help decide the right doses for future studies in people with COVID-19.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PA-001
- What this could lead to
- If successful, this could help determine safe doses for future studies of PA-001 as a potential treatment for COVID-19.
- What could go wrong
- This is an early Phase 1 safety study in healthy people, not patients. It does not test if PA-001 actually works against COVID-19, and many early-stage drugs fail to show benefit later.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fortrea Clinical Research Unit Inc.
Dallas, Texas, 75230, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?